{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:58:05Z","timestamp":1792400285409,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vph.2026.107585","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:12:25Z","timestamp":1770077545000},"page":"107585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and\/or selexipag as a part of a combination treatment (INSPECTIO)"],"prefix":"10.1016","volume":"162","author":[{"given":"Michele","family":"D'Alto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Scelsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Piero","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Di Poi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vicenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Badagliacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Corda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Air\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ameri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiuseppe","family":"Agostoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"D'Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavino","family":"Casu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Biancospino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Uglietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.vph.2026.107585_bb0005","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.vph.2026.107585_bb0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.vph.2026.107585_bb0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.vph.2026.107585_bb0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"47","key":"10.1016\/j.vph.2026.107585_bb0025","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"39","author":"Kylhammar","year":"2018","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.vph.2026.107585_bb0030","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01323-2024","article-title":"Risk stratification and treatment goals in pulmonary arterial hypertension","volume":"64","author":"Dardi","year":"2024","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.vph.2026.107585_bb0035","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","article-title":"Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension","volume":"204","author":"Boucly","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.vph.2026.107585_bb0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.vph.2026.107585_bb0045","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.vph.2026.107585_bb0050","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.vph.2026.107585_bb0055","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00673-2020","article-title":"Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension","volume":"56","author":"Sitbon","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.vph.2026.107585_bb0060","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jcmg.2021.07.027","article-title":"The REPAIR study: effects of macitentan on RV structure and function in pulmonary arterial hypertension","volume":"15","author":"Vonk Noordegraaf","year":"2022","journal-title":"JACC Cardiovasc. Imag."},{"issue":"3","key":"10.1016\/j.vph.2026.107585_bb0065","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019877157","article-title":"Epidemiology and initial management of pulmonary arterial hypertension: real-world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE)","volume":"9","author":"Arvanitaki","year":"2019","journal-title":"Pulm. Circ."},{"issue":"6","key":"10.1016\/j.vph.2026.107585_bb0070","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02024-2021","article-title":"Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry","volume":"59","author":"Hoeper","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.vph.2026.107585_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2014.07.013","article-title":"Effect of macitentan on hospitalizations: results from the SERAPHIN trial","volume":"3","author":"Channick","year":"2015","journal-title":"JACC Heart Fail."},{"issue":"1","key":"10.1016\/j.vph.2026.107585_bb0080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.chest.2016.08.1473","article-title":"Macitentan improves health-related quality of life for patients with pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trial","volume":"151","author":"Mehta","year":"2017","journal-title":"Chest"},{"issue":"15","key":"10.1016\/j.vph.2026.107585_bb0085","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/eurheartj\/ehx025","article-title":"SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension","volume":"38","author":"Gali\u00e8","year":"2017","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.vph.2026.107585_bb0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ejhf.2369","article-title":"The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study","volume":"24","author":"Rosenkranz","year":"2022","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.vph.2026.107585_bb0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-017-0262-z","article-title":"Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized controlled GRIPHON study","volume":"18","author":"Coghlan","year":"2018","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"7","key":"10.1016\/j.vph.2026.107585_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011220","article-title":"Research studies on patients\u2019 illness experience using the narrative medicine approach: a systematic review","volume":"6","author":"Fioretti","year":"2016","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.vph.2026.107585_bb0105","first-page":"176","article-title":"What is narrative-based medicine? Narrative-based medicine 1","volume":"64","author":"Zaharias","year":"2018","journal-title":"Can. Fam. Physician"},{"issue":"4","key":"10.1016\/j.vph.2026.107585_bb0110","first-page":"286","article-title":"Narrative-based medicine and the general practice consultation: narrative-based medicine 2","volume":"64","author":"Zaharias","year":"2018","journal-title":"Can. Fam. Physician"},{"issue":"5","key":"10.1016\/j.vph.2026.107585_bb0115","first-page":"352","article-title":"Learning narrative-based medicine skills: narrative-based medicine 3","volume":"64","author":"Zaharias","year":"2018","journal-title":"Can. Fam. Physician"},{"issue":"5402","key":"10.1016\/j.vph.2026.107585_bb0120","first-page":"177","article-title":"Code of ethics of the world medical association. Declaration of Helsinki","volume":"2","author":"Rickhman","year":"1964","journal-title":"Br. Med. J."},{"issue":"6","key":"10.1016\/j.vph.2026.107585_bb0125","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clinthera.2024.04.010","article-title":"Effectiveness of a prostacyclin IP receptor agonist in patients with pulmonary arterial hypertension in the real-world Andalusian setting: the RAMPHA study","volume":"46","author":"Bravo-Marques","year":"2024","journal-title":"Clin. Ther."},{"issue":"9","key":"10.1016\/j.vph.2026.107585_bb0130","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1007\/s12325-024-02946-2","article-title":"Four-strata risk assessment in patients with pulmonary arterial hypertension treated with selexipag in real-world settings (EXPOSURE study)","volume":"41","author":"Lange","year":"2024","journal-title":"Adv. Ther."},{"issue":"12","key":"10.1016\/j.vph.2026.107585_bb0135","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2459\/JCM.0000000000001250","article-title":"Assessment of right ventricle in pulmonary arterial hypertension with three-dimensional echocardiography and cardiovascular magnetic resonance","volume":"22","author":"Lattanzio","year":"2021","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"issue":"2","key":"10.1016\/j.vph.2026.107585_bb0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2459\/JCM.0000000000001574","article-title":"Right ventricle assessment before tricuspid valve interventions","volume":"25","author":"Cersosimo","year":"2024","journal-title":"J. Cardiovasc. Med. (Hagerstown)"}],"updated-by":[{"DOI":"10.1016\/j.vph.2026.107588","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000}},{"DOI":"10.1016\/j.vph.2026.107588","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000}}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189126000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189126000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:15:02Z","timestamp":1781334902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189126000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"alternative-id":["S1537189126000054"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2026.107585","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world observational study on pulmonary arterial hypertension: Italian cohort treated with macitentan and\/or selexipag as a part of a combination treatment (INSPECTIO)","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2026.107585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107585"}}